My ePortfolio Register   

FALCON: Impact of 18F-fluciclovine PET/CT on management of biochemically recurrent prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.02.18
Views: 225

Dr Eugene Teoh - University of Oxford, Oxford, UK

Dr Teoh speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about the FALCON trial looking at the impact of using fluciclovine, as a PET imaging radiotracer, on the clinical and treatment decision required for managing patients with biochemically recurrent prostate cancer who are being considered for salvage treatment with the intention of providing disease cure.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence